Spyre Therapeutics shares fell 12% after the company announced a $350 million public stock offering. The offering consists of about 4.12 million shares at $85 each, with underwriters having a 30-day option to buy up to an additional $52.5 million. Proceeds will fund drug candidates in gastroenterology, rheumatology, and dermatology. The offering is expected to close Wednesday.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
